Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

19.10B

Market cap19.10B

Price-Earnings ratio

13.68

Price-Earnings ratio13.68

Dividend yield

—

Dividend yield—

Average volume

1.29M

Average volume1.29M

High today

$96.83

High today$96.83

Low today

$94.21

Low today$94.21

Open price

$96.48

Open price$96.48

Volume

1.55M

Volume1.55M

52 Week high

$112.29

52 Week high$112.29

52 Week low

$63.93

52 Week low$63.93

Stock Snapshot

With a market cap of 19.1B, Incyte(INCY) trades at $95.59. The stock has a price-to-earnings ratio of 13.68.

On 2026-06-01, Incyte(INCY) stock moved within a range of $94.21 to $96.83. With shares now at $95.59, the stock is trading +1.5% above its intraday low and -1.3% below the session's peak.

Trading volume for Incyte(INCY) stock has reached 1.55M, versus its average volume of 1.29M.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $63.93.

INCY News

Investing.com 8h

Stifel reiterates Incyte stock Buy rating on DLBCL data strength - Investing.com

...

TipRanks 9h

Incyte Buy Rating Reiterated as Analyst Highlights Robust Pipeline, Clinical Catalysts and Maintains $124 Price Target

Incyte, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tazeen Ahmad from Bank of America Securities maintained a Buy ratin...

TipRanks 10h

Incyte Buy Rating Reiterated as Monjuvi Data Support Diversification; $135 Price Target Maintained

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Incyte. The associated price target remains the same with $135.00. Claim 55% Off...

Analyst ratings

57%

of 30 ratings

Buy

36.7%

Hold

56.7%

Sell

6.7%

More INCY News

Simply Wall St 10h

A Look At Incyte Valuation After Positive frontMIND Phase 3 Lymphoma Trial Results

Advertisement Why the frontMIND trial update matters for Incyte (INCY) Incyte (INCY) is in focus after reporting that its pivotal Phase 3 frontMIND trial in p...

TipRanks 1d

Incyte announces results from Phase 3 frontMIND trial on tafasitamab

Incyte (INCY) announced positive results from the Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab, a humanized Fc-modified cytolytic C...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Credo Technology Group

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.